Literature DB >> 30291113

Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.

Catharina Schuetz1, Manfred Hoenig1, Despina Moshous2,3, Christof Weinstock4, Martin Castelle2, Matthieu Bendavid2, Kristin Shimano5, Vanessa Tolbert5, Ansgar S Schulz1, Christopher C Dvorak5.   

Abstract

New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.
© 2018 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30291113      PMCID： PMC6177653          DOI： 10.1182/bloodadvances.2018020883

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  6 in total

Review 1.  An update on the role of daratumumab in the treatment of multiple myeloma.

Authors:  Caitlin Costello
Journal:  Ther Adv Hematol       Date:  2016-11-24

2.  The multi-faceted potential of CD38 antibody targeting in multiple myeloma.

Authors:  Rory M Shallis; Christopher M Terry; Seah H Lim
Journal:  Cancer Immunol Immunother       Date:  2017-03-24       Impact factor: 6.968

3.  The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant.

Authors:  Ibrahim Ahmed; Jun Teruya; Cristina Murray-Krezan; Robert Krance
Journal:  Pediatr Transplant       Date:  2015-03-23

4.  Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.

Authors:  Emma Watz; Mats Remberger; Olle Ringden; Joachim Lundahl; Per Ljungman; Jonas Mattsson; Agneta Wikman; Michael Uhlin
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-22       Impact factor: 5.742

5.  Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience.

Authors:  Maura Faraci; Marco Zecca; Marta Pillon; Attilio Rovelli; Maria Cristina Menconi; Mimmo Ripaldi; Franca Fagioli; Marco Rabusin; Ottavio Ziino; Edoardo Lanino; Franco Locatelli; Thomas Daikeler; Arcangelo Prete
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-23       Impact factor: 5.742

Review 6.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Authors:  Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988
  6 in total
  24 in total

Review 1.  Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review.

Authors:  Yazan Migdady; Asiri Ediriwickrema; Ryan Patrick Jackson; Wendy Kadi; Ridhi Gupta; Francisco Socola; Sally Arai; Beth A Martin
Journal:  Blood Adv       Date:  2020-03-10

Review 2.  Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.

Authors:  Geoffrey D E Cuvelier; Michelle Schoettler; Nataliya P Buxbaum; Iago Pinal-Fernandez; Marc Schmalzing; Jörg H W Distler; Olaf Penack; Bianca D Santomasso; Robert Zeiser; Klemens Angstwurm; Kelli P A MacDonald; W Taylor Kimberly; Naomi Taylor; Ervina Bilic; Bernhard Banas; Maike Buettner-Herold; Namita Sinha; Hildegard T Greinix; Joseph Pidala; Kirk R Schultz; Kirsten M Williams; Yoshihiro Inamoto; Corey Cutler; Linda M Griffith; Stephanie J Lee; Stefanie Sarantopoulos; Steven Z Pavletic; Daniel Wolff
Journal:  Transplant Cell Ther       Date:  2022-05-31

Review 3.  Development of New Drugs for Autoimmune Hemolytic Anemia.

Authors:  Zhengrui Xiao; Irina Murakhovskaya
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

4.  Clinical and surgical outcomes of splenectomy for autoimmune hemolytic anemia.

Authors:  Sara Maskal; Raha Al Marzooqi; Aldo Fafaj; Samuel Zolin; Robert Naples; Advait Iyer; Clayton Petro; David Krpata; Ajita Prabhu; Michael Rosen; Steven Rosenblatt
Journal:  Surg Endosc       Date:  2022-02-22       Impact factor: 3.453

5.  Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies.

Authors:  Sebastian Ochoa; Li Ding; Samantha Kreuzburg; Jennifer Treat; Steven M Holland; Christa S Zerbe
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

6.  Characterizing Immune-Mediated Cytopenias After Allogeneic Hematopoietic Cell Transplantation for Pediatric Nonmalignant Disorders.

Authors:  Robert T Galvin; Qing Cao; Weston P Miller; Jessica Knight-Perry; Angela R Smith; Christen L Ebens
Journal:  Transplant Cell Ther       Date:  2021-01-20

Review 7.  Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.

Authors:  Ashish O Gupta; Jaap Jan Boelens; Christen L Ebens; Joanne Kurtzberg; Troy C Lund; Angela R Smith; John E Wagner; Robert Wynn; Bruce R Blazar; Paul J Orchard
Journal:  Bone Marrow Transplant       Date:  2021-01-13       Impact factor: 5.174

Review 8.  Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab.

Authors:  Marilyn T Nedumcheril; Robert A DeSimone; Sabrina E Racine-Brzostek; Ok Kyong Chaekal; Ljiljana V Vasovic
Journal:  J Blood Med       Date:  2021-05-25

9.  Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives.

Authors:  Wilma Barcellini; Bruno Fattizzo; Anna Zaninoni
Journal:  J Blood Med       Date:  2019-08-08

Review 10.  Inborn Errors of Immunity With Immune Dysregulation: From Bench to Bedside.

Authors:  Ottavia Maria Delmonte; Riccardo Castagnoli; Enrica Calzoni; Luigi Daniele Notarangelo
Journal:  Front Pediatr       Date:  2019-08-27       Impact factor: 3.418
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.